• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of JINAD study submissions completed on time

Dictionary: Sponsors may submit data intended to support an application for a generic new animal drug approval during the investigation of the generic new animal drug to a JINAD file. A study submission is a submission containing both the data and conclusions of a study to be considered in support of the approval of a generic new animal drug.

Note: October 1, 2008 is the effective date of the AGDUFA.

Information is current as of December 31, 2013.

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetPercent
Oct 201090100
Nov 201090-
Dec 201090100
Jan 201190-
Feb 201190100
Mar 201190-
Apr 201190-
May 201190100
Jun 201190100
Jul 201190100
Aug 201190100
Sep 201190100

FY 2011 Overall: 100

Footnotes

  • This metric is also an Animal Generic Drug User Fee Program performance goal. In the yearly performance report to Congress, performance is reported for a defined fiscal year receipt cohort. The methodology for reporting by fiscal year receipt cohort calculates performance statistics for submissions for the fiscal year FDA received them, regardless of when FDA ultimately acted on or approved the submissions. The data reported here is the measurement of the number of applications reviewed in a given month regardless of the cohort year.

Number of JINAD study submissions completed on time

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A2
Nov 2010N/A0
Dec 2010N/A1
Jan 2011N/A0
Feb 2011N/A2
Mar 2011N/A0
Apr 2011N/A0
May 2011N/A3
Jun 2011N/A4
Jul 2011N/A2
Aug 2011N/A1
Sep 2011N/A5

FY 2011 Total: 20

Number of JINAD study submissions completed within the month

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A2
Nov 2010N/A0
Dec 2010N/A1
Jan 2011N/A0
Feb 2011N/A2
Mar 2011N/A0
Apr 2011N/A0
May 2011N/A3
Jun 2011N/A4
Jul 2011N/A2
Aug 2011N/A1
Sep 2011N/A5

FY 2011 Total: 20

Glossary

JINAD

Generic Investigational New Animal Drug

AGDUFA

Animal Generic Drug User Fee Act

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.